- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02727959
Inflammatory Bowel Disease in South Eastern Norway (IBSENIII)
Inflammatory Bowel Disease in South Eastern Norway (IBSEN III). Clinical Epidemiology, Diagnostic and Prognostic Factors in Inflammatory Bowel Disease.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway, 0871
- Oslo University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Ulcerative colitis:
Diagnostic criteria (at least three out of four criteria present):
- A history of diarrhea and/or pus in stools for more than 4weeks or repeated episodes.
- Macroscopic appearance at endoscopy of continuous mucosal inflammation affecting the rectum in continuity with some or the entire colon.
- Microscopic features on biopsy compatible with UC,
- No suspicion of CD on small bowel X-ray, ileocolonoscopy or biopsy.
Crohn's disease:
Diagnostic criteria (at least two of four criteria present):
- History of abdominal pain, weight loss and/or diarrhea for more than three months.
- Characteristic endoscopic findings of ulceration (aphthous lesions, snail track ulceration) or cobble stoning or radiological features of stricture or cobble stoning.
- Histopathology consistent with Crohn's disease (epitheloid granuloma of Langerhans type or transmural discontinuous focal or patchy inflammation).
- Fistula and/or abscess in relation to affected bowel segments.
Inflammatory bowel disease, type unclassified (IBDU) :
Patients with evidence on clinical and endoscopic grounds for chronic inflammatory bowel disease affecting the colon, without small bowel involvement, and no definitive histological or other evidence to favor either CD or UC.
Pediatric patients:
Will be diagnosed according to the Porto-criteria and defined as:
Pediatric onset IBD ≤ 16 years Early Onset IBD (EOIBD) < 10 years Very Early Onset IBD (VEOIBD) < 6 years Infantile (and toddler) IBD < 2 years Neonatal IBD < 28 days
Exclusion criteria:
- Other causes of acute or chronic bowel inflammation must be excluded, i.e. infectious colitis, radiation colitis, diversion colitis, solitary rectal ulcer syndrome, graft versus host disease, diverticular colitis, medication associated colitis, ischemic colitis, microscopic colitis, enema associated colitis.
- Refusal or not able to give informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients newly diagnosed with IBD
|
Symptomatic non IBD-controls
Patients referred with symptoms suspicious of IBD, but who, after examination, are found not to have the diagnosis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evidence for ulcerative colitis, Crohn's disease or indeterminate colitis based on specific clinical, endoscopic, histological and radiological criteria
Time Frame: At baseline
|
Diagnosis according to the Lennard Jones Criteria for the diagnosis of inflammatory bowel disease
|
At baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in IBD diagnosis between baseline and one year follow-up
Time Frame: 1 year (+/-3 months)
|
Change in diagnosis based on specified clinical, endoscopic, histological and radiological criteria
|
1 year (+/-3 months)
|
Change in IBD diagnosis between one year and five year follow-up
Time Frame: 5 year (+/-3 months)
|
Change in diagnosis based on specified clinical, endoscopic, histological and radiological criteria
|
5 year (+/-3 months)
|
Change in disease classification (montreal Classification) between baseline and one year follow-up.
Time Frame: 1 year (+/-3 months)
|
Change in disease extension and severity as defined in the Montreal classification system for IBD
|
1 year (+/-3 months)
|
Change in disease classification (montreal Classification) between one and five year follow-up
Time Frame: 5 year (+/-3 months)
|
Change in disease extension and severity as defined in the Montreal classification system for IBD
|
5 year (+/-3 months)
|
IBD related bowel surgery
Time Frame: 1 year (+/-3 months)
|
Bowel surgery for any IBD related condition
|
1 year (+/-3 months)
|
IBD related bowel surgery
Time Frame: 5 year (+/-3 months)
|
Bowel surgery for any IBD related condition
|
5 year (+/-3 months)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 581912
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Sheba Medical CenterActive, not recruiting
-
NHS Greater Glasgow and ClydeUnknown